The Article Covers Cabin Size, Sleeping Arrangements, Amenities, and Location Factors That Can Shape a Family or Group Stay

BROKEN BOW, Okla., Oct. 21, 2026 /PRNewswire/ -- How do you choose the right Broken Bow cabin for your group? HelloNation published an article with the answer, featuring insights from Janine Carter of Beavers Bend Adventures Inc. in Broken Bow, Oklahoma.

The article explains that choosing a Broken Bow cabin begins with understanding how the group plans to use the property. Total square footage may be less important than bedroom arrangements, bathrooms, gathering spaces, and location. Cabin Rental Expert Janine Carter is featured as the source of insights on these practical considerations.

According to the article, travelers should first consider who is going and how each person prefers to sleep. Couples may value private bedrooms, while children may be comfortable in bunk rooms. Teenagers may benefit from a separate sleeping area or game room where they can spend time together.

The article notes that advertised guest capacity does not always tell the full story about cabin size. A property that sleeps 12 could depend on bunk beds, sleeper sofas, or shared bedrooms. Reviewing the actual bed configuration helps families determine whether the sleeping arrangements fit the ages and relationships within their group.

Bathrooms are another practical factor the article discusses. A cabin with many beds but limited bathrooms can create crowded mornings and evenings. Families with younger children may also find it helpful to have bathrooms located close to sleeping areas.

The HelloNation article also examines shared indoor spaces for a family trip. An open living area can accommodate meals and conversation, while a separate game room can give children and teenagers another place to gather. This extra indoor space may become especially useful during rainy weather or longer visits.

Kitchen features should also match the group's plans. The article recommends considering refrigerator capacity, counter space, dining seating, and available cookware when guests expect to prepare meals. For larger groups, a functional kitchen and dining area may be more useful than features the group will rarely use.

Outdoor areas are another part of evaluating a family-friendly cabin. Covered decks can provide gathering space when weather changes, while fire pits, hot tubs, seating, and play areas may suit different ages and interests. The article advises comparing cabin amenities with activities the group can realistically enjoy.

For families with children, the article explains that practical layout details can make a difference. Bunk rooms, shared spaces, and recreation areas may help, but parents should also consider stairs, deck design, and distances between bedrooms. Cabin Rental Expert Janine Carter's insights help frame these details around how families actually use a property.

Location can influence the experience as much as the cabin itself. The article notes that some groups prefer quieter surroundings, while others value convenient access to restaurants and attractions. Frequent outings can make driving time, road access, parking, steep roads, and seasonal conditions important considerations.

The article concludes that selecting a Broken Bow cabin involves balancing privacy, shared space, location, and practical amenities. Rather than choosing a property based on its longest list of features, travelers can focus on the features that support their group's plans.

How to Choose the Right Broken Bow Cabin for Your Group features insights from Janine Carter, Broken Bow, Oklahoma, Cabin Rental Expert, in HelloNation.

About HelloNation

HelloNation is America's Good News Network, a premier media platform built on the idea that good news travels faster when real people tell real stories. Through its community-focused publications and innovative "edvertising" approach, HelloNation delivers content that informs, inspires, and spotlights the leaders making a meaningful impact in their communities.

SOURCE HelloNation

Share this article

DELRAY BEACH, Fla., Oct. 21, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Regenerative Medicine Market is projected to reach USD 62.69 billion by 2031 from USD 23.90 billion in 2026, at a CAGR of 21.3% during the forecast period.

Browse 297 market data Tables and 57 Figures spread through 295 Pages and in-depth TOC on "Regenerative Medicine Market - Global Forecast to 2031"

Regenerative Medicine Market Size & Forecast:

- Market Size Available for Years: 2026–2031

- 2026 Market Size: USD 23.90 billion

- 2031 Projected Market Size: USD 62.69 billion

- CAGR (2026–2031): 21.3%

Regenerative Medicine Market Trends & Insights:

- North America accounted for the largest market share of ~52.3% in 2025.

- By product, cell therapy segment accounted for the largest market share of ~47.6% in 2025.

- By therapeutic area, oncology is the fastest-growing segment, registering a CAGR of 22.3% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65442579

The growth of the regenerative medicine market is characterized by increasing collaborations and partnerships among major market players and the emerging applications in new therapeutic areas. Rising focus on personalized medicine and increasing regulatory approvals in regenerative medicine are also predicted to drive the market.

The cell therapy segment accounted for the largest share of the regenerative medicine market.

Based on product, the regenerative medicine market is segmented into cell therapy, gene therapy, and tissue engineering. Cell therapy includes stem cell therapy, cell transplantations, stem cell therapy products such as autologous and allogeneic therapies, and cell-based immunotherapy products. Expanding adoption of CAR-T and other cellular therapies, increasing stem cell applications, growing treatment-center capabilities, and continued regulatory approvals are supporting the segment's growth. Gene therapy and tissue engineering are also gaining momentum as developers broaden disease targets and advance regenerative approaches for tissue repair and functional restoration.

The musculoskeletal disorder segment accounts for the largest share of the regenerative medicine market.

By therapeutic area, the regenerative medicines market covers oncology, musculoskeletal disorders, dermatology & wound care, cardiovascular diseases, ophthalmology, neurology, and other applications. Musculoskeletal applications remain important due to the high burden of orthopedic disorders, cartilage and bone injuries, and growing research into regenerative approaches for tissue repair. At the same time, cell-based immunotherapies continue to expand in oncology, while gene therapies are broadening treatment options in neurological and ophthalmic diseases. Tissue-engineered products are gaining use in wound care and reconstructive applications.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=65442579

North America dominated the global regenerative medicine market in 2025.

North America accounts for the largest share of the global regenerative medicine market, closely followed by Europe and Asia Pacific. This can be attributed to the growth of stem cell research, healthcare sector expansion, and the increase in the adoption of stem cell therapy and cell immunotherapies for cancer and other chronic disease treatment.

Key Players

Leading players in the Regenerative Medicine companies include Novartis AG (Switzerland), Biogen, Inc. (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Amgen Inc. (US), Vericel Corporation (US), MIMEDX Group, Inc. (US), Organogenesis Inc. (US), Medtronic plc (Ireland), and Bristol-Myers Squibb Company (US).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=65442579

Regenerative Medicine Market- Investment & funding +Merger & Acquisition

Investment Funding Context

The regenerative medicine market continues to attract substantial venture capital and government funding across cell therapy, gene therapy, and tissue engineering, with investment increasingly directed toward clinical-stage assets, next-generation manufacturing platforms, and technologies capable of improving scalability and patient access. In January 2025, Aspect Biosystems raised USD 115 million in Series B financing to advance its bioprinted tissue therapeutics platform, which integrates therapeutic cells, biomaterials, AI-enabled bioprinting, and tissue engineering technologies. In April 2025, Neurona Therapeutics secured USD 102 million to support the Phase III development of NRTX-1001, a regenerative cell therapy for epilepsy, and advance its broader cell therapy pipeline. Neurona Therapeutics Public-sector funding also remains significant; the California Institute for Regenerative Medicine approved a USD 662 million research budget for FY2026–27, its largest annual investment to date, to accelerate stem cell and gene therapy research and clinical development. Additionally, ARPA-H committed up to USD 87 million under its BioStabilization Systems program to develop room-temperature preservation technologies for cell-based biologics, highlighting investment in infrastructure intended to reduce cold-chain dependence and improve therapy accessibility. These developments indicate sustained funding across therapeutic development, manufacturing, preservation, and commercialization capabilities.

Revenue Shift Context

The regenerative medicines market is gradually transitioning from a predominantly research- and clinical-stage industry toward a broader commercial revenue base, supported by increasing uptake of approved cell therapies, gene therapies, and tissue-engineered products. In 2025, CARVYKTI generated approximately USD 1.9 billion in worldwide sales, with Johnson & Johnson attributing growth partly to continued share gains and manufacturing capacity expansion. SEC Bristol Myers Squibb reported USD 1.36 billion in Breyanzi revenue and USD 427 million from Abecma, illustrating the expanding commercial contribution of CAR-T therapies. Gilead's cell therapy revenue declined 7% to USD 1.8 billion in 2025, including USD 1.5 billion from Yescarta and USD 344 million from Tecartus, reflecting increasing competition within established CAR-T indications. Overall, revenue opportunities are increasingly shifting toward commercially validated therapies, expanded indications, manufacturing capacity, and broader penetration of regenerative products across oncology, musculoskeletal disorders, and wound care.

Mergers and Acquisitions

Mergers and acquisitions in the regenerative medicine market during January 2025–July 2026 have increasingly focused on strengthening cell therapy, gene therapy, and regenerative medicine pipelines, while gaining access to differentiated delivery platforms, late-stage therapeutic assets, and commercial manufacturing capabilities. Large pharmaceutical and healthcare companies are using acquisitions to expand into CAR-T and in vivo cell therapies, ophthalmic regenerative therapies, neurological cell therapies, and commercial gene therapy portfolios. These transactions also reflect growing interest in technologies that can simplify manufacturing, improve scalability, and broaden patient access to advanced therapies.

REGENERATIVE MEDICINE MARKET: MERGERS AND ACQUISITIONS, JANUARY 2025–JULY 2026

Company Revenue Share Details

The total market share of the top five players in the regenerative medicine market is estimated at around 40–45%, indicating a moderately concentrated competitive landscape. Leading participants include Sarepta Therapeutics, Gilead Sciences, Bristol Myers Squibb, Novartis, and Biogen, which collectively hold a significant share of the market through their established portfolios across gene therapy, cell-based immunotherapy, and other regenerative medicine products.

These companies compete on the basis of commercialized product portfolios, clinical pipeline strength, therapeutic efficacy, regulatory approvals, manufacturing capabilities, geographic reach, and strategic collaborations. The market also includes a broad base of mid-sized and emerging regenerative medicine companies focused on stem cell therapy, tissue engineering, wound care, musculoskeletal regeneration, and next-generation cell and gene therapies. Competition is expected to intensify as companies expand indications, scale manufacturing capacity, pursue acquisitions and licensing agreements, and develop advanced autologous, allogeneic, and gene-modified therapies across oncology, musculoskeletal disorders, neurology, ophthalmology, and other therapeutic areas.

Browse Adjacent Market: Biotechnology Market Research Reports &Consulting

See More Latest Biotechnology Reports:

CAR T-Cell Therapy Market by Product (Abecma, Breyanzi, Carvykti, Yescarta, Tecartus, Kymriah), Target (CD19, BCMA), Indication (Multiple Myeloma, Leukemia, Lymphoma), Demographic (Adult, Pediatric), Region, Competitive Landscape - Global Forecast to 2031

Stem Cell Therapy Market by Cell Source (Adipose Tissue, Bone Marrow, Placenta, Umbilical Cord, iPSC), Type (Autologus Stem Cell), Therapeutic Application (Musculoskeletal, Wounds, Surgeries, Cardiovascular, Neurological), End User - Global Forecast to 2035

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth.

DelveInsight's analysis predicts significant growth in the cystic fibrosis market from 2026 to 2036, driven by the launch of emerging therapies such as Lonodelestat (Spexis), LAU-7b (Laurent Pharmaceuticals), ARCT-032 (Arcturus Therapeutics), 4D-710 (4D Molecular Therapeutics), KB407 (Krystal Biotech), and others, and increased global healthcare spending. The introduction of new treatments and rising healthcare investments will expand market opportunities and improve patient outcomes.

LAS VEGAS, Oct. 21, 2026 /PRNewswire/ -- Recently published Cystic Fibrosis Market Insights report includes a comprehensive understanding of current treatment practices, cystic fibrosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Cystic Fibrosis Market Summary

- The total cystic fibrosis treatment market size is expected to grow positively by 2036 in the leading markets.

- The United States accounted for the largest cystic fibrosis treatment market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

- There were around 35K diagnosed prevalent cases of cystic fibrosis in the US in 2025, with this number projected to rise over the forecast period from 2026 to 2036.

- Leading cystic fibrosis companies, such as Spexis, Laurent Pharmaceuticals, Arcturus Therapeutics, 4D Molecular Therapeutics, Krystal Biotech, SpliSense, ReCode Therapeutics, Vertex Pharmaceuticals, and others, are developing new cystic fibrosis treatment drugs that can be available in the cystic fibrosis market in the coming years.

- The promising cystic fibrosis therapies in clinical trials include Lonodelestat, LAU-7b, ARCT-032, 4D-710, KB407, SPL84, SPL23, RCT2100, Ivacaftor, and others.

Discover the future of the cystic fibrosis therapeutics market @ https://www.delveinsight.com/report-store/cystic-fibrosis-market

Key Factors Driving the Growth of the Cystic Fibrosis Market

- Rising Prevalence of Cystic Fibrosis: The growing prevalence and continued identification of cystic fibrosis cases are expanding the overall patient pool requiring long-term treatment and disease management. Improved disease recognition and screening are also contributing to higher case detection across various regions.

- Expanding Adoption of CFTR Modulators: Increasing use of CFTR modulator therapies is a major market driver, particularly as more patients become eligible for genotype-specific treatments. Wider adoption of highly effective modulator combinations is improving clinical outcomes and supporting sustained treatment demand.

- Increasing Focus on Personalized Medicine: Greater understanding of CFTR mutations is enabling treatment strategies tailored to individual genetic profiles. The growing emphasis on precision medicine is supporting the development and adoption of mutation-specific and personalized therapeutic approaches.

- Development of Next-Generation Therapies: Pharmaceutical companies are pursuing novel therapies, including Lonodelestat (Spexis), LAU-7b (Laurent Pharmaceuticals), ARCT-032 (Arcturus Therapeutics), 4D-710 (4D Molecular Therapeutics), KB407 (Krystal Biotech), SPL84 and SPL23 (SpliSense), RCT2100 (ReCode Therapeutics), Ivacaftor (Vertex Pharmaceuticals), and others. These innovations could expand treatment options for patients who remain underserved by existing therapies.

Shikha Bhardwaj, Associate Consultant of Forecasting & Analytics at DelveInsight, said, "ALYFTREK demonstrates strong clinical and commercial value, with the potential to deliver improved patient outcomes and convenient once-daily dosing, supported by rapid NHS access and reimbursement agreements that are enhancing adoption."

Cystic Fibrosis Market Analysis

- The cystic fibrosis treatment landscape is undergoing significant transformation, largely driven by the widespread adoption of CFTR modulators, which are now accessible to the majority of eligible patients. This shift is positioning cystic fibrosis increasingly as a chronic, manageable condition.

- However, substantial unmet needs remain among patients who are not eligible for CFTR modulators, while persistent disparities in global treatment access continue to influence innovation and market expansion.

- The cystic fibrosis market is largely dominated by CFTR modulators, with Vertex Pharmaceuticals maintaining a strong leadership position through its portfolio of ALYFTREK, TRIKAFTA, SYMDEKO, and ORKAMBI, which collectively contribute a significant share of global market revenues.

- Market expansion is being supported by broader access and label extensions for CFTR modulators, including their use in younger age groups and patients with a wider range of CFTR mutations.

- The market is anticipated to experience steady growth, supported by sustained uptake of established therapies and the emergence of novel treatments offering improved efficacy, broader patient coverage, and potentially disease-modifying effects.

- The evolving pipeline, which includes candidates such as Lonodelestat, LAU-7b, and ARCT-032, among others, highlights ongoing efforts to address residual unmet needs, expand treatment options, and further improve outcomes for patients with cystic fibrosis.

Cystic Fibrosis Competitive Landscape

Some of the cystic fibrosis drugs under development include Lonodelestat (Spexis), LAU-7b (Laurent Pharmaceuticals), ARCT-032 (Arcturus Therapeutics), 4D-710 (4D Molecular Therapeutics), KB407 (Krystal Biotech), SPL84 and SPL23 (SpliSense), RCT2100 (ReCode Therapeutics), Ivacaftor (Vertex Pharmaceuticals), and others.

Spexis' Lonodelestat is an investigational inhaled therapy designed to inhibit neutrophil elastase, an enzyme associated with pulmonary inflammation and tissue damage in patients with cystic fibrosis. By blocking neutrophil elastase activity, Lonodelestat is intended to reduce lung inflammation and potentially preserve or improve pulmonary function. The therapy is currently being evaluated in Phase II clinical trials to assess its safety and efficacy in cystic fibrosis. Findings from these studies will help determine its potential for further development, regulatory approval, and clinical use.

Laurent Pharmaceuticals' LAU-7b (fenretinide) is a novel oral formulation of fenretinide, an atypical retinoid that modulates specific cell membrane lipids involved in viral replication and immune-inflammatory pathways. As the company's lead drug candidate, LAU-7b is a patent-protected oral formulation designed to support a convenient once-daily, low-dose treatment regimen. The candidate has completed Phase II clinical development for cystic fibrosis.

Arcturus Therapeutics' ARCT-032 is an investigational inhaled mRNA therapy delivered using LUNAR, a lipid-mediated delivery platform that encapsulates mRNA within lipid nanoparticles. In February 2024, the European Commission granted Orphan Medicinal Product Designation to ARCT-032 for the treatment of cystic fibrosis following a positive opinion from the European Medicines Agency. The candidate had previously received Rare Pediatric Disease Designation from the FDA in October 2023 and Orphan Drug Designation in November 2023. In October 2025, the company reported interim results from its ongoing Phase II clinical trial evaluating ARCT-032 in patients with cystic fibrosis.

4D Molecular Therapeutics' 4D-710 is an investigational genetic medicine candidate that utilizes the A101 vector to target the underlying cause of cystic fibrosis lung disease. The candidate is being evaluated in a Phase 1/2 clinical study in patients with cystic fibrosis who are ineligible for CFTR modulator therapy or have discontinued treatment because of adverse effects. 4D-710 is designed for single-dose aerosol administration to deliver a corrective CFTRΔR transgene throughout the airways and alveoli. Its mutation-agnostic approach is intended to provide a disease-modifying effect regardless of the patient's specific CFTR mutation.

The anticipated launch of these emerging therapies are poised to transform the cystic fibrosis market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the cystic fibrosis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about the cystic fibrosis treatment pipeline @ Cystic Fibrosis Drug Pipeline

Cystic Fibrosis Epidemiology Segmentation

The cystic fibrosis epidemiology section provides insights into the historical and current cystic fibrosis patient pool and forecasted trends for the leading markets. Recent trends in cystic fibrosis indicate that Staphylococcus aureus and Pseudomonas aeruginosa remain the most prevalent pathogens, driving a large share of infections.

Mérieux NutriSciences Completes Acquisition of Certified Group, Becoming North America's Leading Food Testing Provider

CHICAGO, Oct. 21, 2026 /PRNewswire/ -- Mérieux NutriSciences, a global leader in food safety, quality, and sustainability, today announced the successful completion of its acquisition of Certified Group.

First announced in August 2026, this strategic transaction unites two complementary leaders in the Testing, Inspection, and Certification (TIC) sector. With approximately $300 million in revenue, Certified Group brings 31 laboratories and over 1,600 talented employees into Mérieux NutriSciences' global network. The integration also adds a robust roster of more than 170 independent regulatory consultants across the United States and Canada.

With this expanded coast-to-coast footprint, Mérieux NutriSciences is positioned to provide customers with broader service offerings and enhanced regulatory support. The integration deepens the company's capabilities in key Food & Beverage segments, most notably in animal protein through its Food Safety Net Services (FSNS) network, where Certified Group has built a strong reputation as a bellwether for safety and quality, alongside leading positions in dairy, packaged foods, nuts, and spices.

Customers will also benefit from high-value expertise in cosmetics, OTC products, and dietary supplements through the Certified Laboratories vertical, and reduced-harm nicotine product testing via Labstat International. These core verticals are further bolstered by specialized expert services, including contract research (Lab Plus), regulatory consulting (EAS Consulting Group), and comprehensive certification and audit programs (FSNS Certification and Audit).

"We are thrilled to officially welcome the talented teams from Certified Group to the Mérieux NutriSciences global network," said Nicolas Cartier, CEO of Mérieux NutriSciences. "By combining our respective strengths, we are vastly expanding the depth and breadth of our capabilities. This milestone allows us to be closer to our customers, meeting their localized, time-sensitive needs with unmatched speed and reliability, while furthering our shared purpose: Better Food. Better Health. Better World."

"Our priority is to ensure a seamless transition for all customers while delivering immediate, enhanced value," added Sébastien Moulard, President North America at Mérieux NutriSciences. "Through this nationwide analytical network, customers now have access to a truly comprehensive portfolio of routine testing, specialized analysis, expert regulatory support, and more. We are excited to leverage the best of both worlds to drive innovation and provide practical solutions right where production happens."

"Certified Group has built a differentiated platform with a strong reputation for quality, scientific excellence and exceptional customer service," said Deborah Kerr, Managing Director, Warburg Pincus & Executive Chair, Certified Group. "We are proud to have supported Certified Group's evolution and look forward to seeing the company continue to thrive as part of Mérieux NutriSciences."

The financing of the acquisition brings new minority shareholders Peugeot Invest and Continental Grain Company (Conti) alongside Mérieux NutriSciences' long standing shareholders: Institut Mérieux, Sofina, and Dassault Group. This collective support underscores strong market confidence in the company's strategic vision. Ultimately, the successful integration of Certified Group solidifies Mérieux NutriSciences as the leading provider in North America and a top player in the global food TIC market, further cementing its role as the trusted partner for customers navigating a rapidly evolving landscape.

About Mérieux NutriSciences:

At Mérieux NutriSciences, we leverage 60 years of scientific and entrepreneurial expertise to answer food industry needs. Today's global challenges transform the way food is produced, marketed and consumed, which is why we know our clients need more than reliable analytical results; they need practical and innovative solutions that will contribute to make food systems safer, healthier and more sustainable. Present worldwide, we are more than 160 accredited laboratories and a team of over 11,600 committed employees. We strongly believe that together, we can create solutions to offer our planet: BETTER FOOD. BETTER HEALTH. BETTER WORLD. na.mxns.com

MERIEUX NUTRISCIENCES

Stephen Nichols (North America)

[email protected] 

Marion Bertrand (Global)

[email protected] 

Ashton van den Bergh (Global)

[email protected]

SOURCE Mérieux NutriSciences

Share this article

Financial institutions, fintechs honored for innovation, impact, and empowering financial freedom

MONETT, Mo., Oct. 21, 2026 /PRNewswire/ -- Jack Henry® (Nasdaq: JKHY) is proud to announce the winners of the 2026 Cobalt Awards – six financial institutions and fintechs that are using innovation, integration, and technology to create meaningful impact for the communities they serve.

This year's honorees, Local Bank, Numerica Credit Union, FirstBank, Kitsap Credit Union, Array, and Moov, were selected for their outstanding achievements in using technology to drive operational excellence, improve financial outcomes, and empower people to move forward with confidence.

The winners were revealed this week during the 2026 Jack Henry® Connect annual client conference.

"The Cobalt Awards celebrate organizations that are finding new ways to strengthen their communities through innovation," said Jack Henry President and CEO Greg Adelson. "We're honored to recognize this year's winners for delivering solutions that improve financial access, enhance efficiency, and help people achieve better financial outcomes."

2026 Cobalt Award Winners

The Barrier Breakers

Recognizes financial institutions for tearing down barriers to financial health

- Local Bank – Expanded financial access and literacy across Native American communities by combining digital banking technology with community-focused outreach and education

- Numerica Credit Union – Helped members save nearly $500,000 in six months through an innovative micro-savings solution that makes saving simple and automatic

The Changemakers

Recognizes financial institutions for outstanding achievements using technology, services, and innovation

- FirstBank – Leveraged Jack Henry's open integration model to create a custom authentication platform that ended contact-center fraud and improved efficiency

- Kitsap Credit Union – Transformed loan quality control through intelligent automation, increasing review coverage to 100% while strengthening operational efficiency and oversight

The Integrators

Recognizes fintechs who are bridging the gap between service and technology delivery, streamlining transaction processing, and helping improve financial outcomes

- Array – Embedded financial wellness capabilities directly into digital banking experiences, helping consumers monitor, manage, and improve their financial health

- Moov – Partnered with Jack Henry to deliver embedded payment solutions that help consumers and small businesses move money faster and manage payments more seamlessly

Each winner is featured in a dedicated case study highlighting its journey, impact, and the technology that helped drive success. Visit jackhenry.com to learn more about the 2026 Cobalt Award winners and their stories.

About Jack Henry & Associates, Inc.®

Jack Henry®(Nasdaq: JKHY) is a well-rounded financial technology company that strengthens connections between financial institutions and the people and businesses they serve. We are an S&P 500 company that prioritizes openness, collaboration, and user centricity – offering banks and credit unions a vibrant ecosystem of internally developed modern capabilities as well as the ability to integrate with leading fintechs. For 50 years, Jack Henry has provided technology solutions to enable clients to innovate faster, strategically differentiate, and successfully compete while serving the evolving needs of their accountholders. We empower more than 7,200 clients with people-inspired innovation, personal service, and insight-driven solutions that help reduce the barriers to financial health. Additional information is available at jackhenry.com.

Statements made in this news release that are not historical facts are "forward-looking statements." Because forward-looking statements relate to the future, they are subject to inherent risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, but are not limited to, those discussed in the Company's Securities and Exchange Commission filings, including the Company's most recent reports on Form 10-K and Form 10-Q, particularly under the heading "Risk Factors." Any forward-looking statement made in this news release speaks only as of the date of the news release, and the Company expressly disclaims any obligation to publicly update or revise any forward-looking statement, whether because of new information, future events or otherwise.

SOURCE Jack Henry & Associates, Inc.

Share this article

New collaborative philanthropy fund pairs its founding donors with ICONIQ Impact to support 18 organizations helping boys and men nationwide build stronger connections, families, and futures.

NEW YORK, Oct. 21, 2026 /PRNewswire/ -- ICONIQ Impact, ICONIQ Capital's platform for collaborative philanthropy, today announced the launch of the Boys & Men Co-Lab, a collaborative philanthropy fund aiming to mobilize $30 million in support of 18 organizations working to help boys and young men by investing in community, fatherhood, and education and skill building for boys and men across the United States.

The Co-Lab's founding donors include Chris Larsen, philanthropist and American business executive, and Lyna Lam; The David and Lucile Packard Foundation; Mo and John Pritzker, co-trustees of the Mojo Philanthropic Fund; Richard V. Reeves, founding president of the American Institute for Boys and Men (AIBM); Jessica Sieja and Andrew Sieja, co-founders of Alta Futures; Dennis Troper, president of Troper Wojcicki Philanthropies; and Maggie and Teddy Vlock, of the Vlock Family Foundation, alongside ICONIQ partner Matt Jacobson and Salima Jacobson. The Co-Lab took shape through a series of conversations among philanthropists, researchers, and practitioners, and reflects the founding donors' shared conviction that boys and men deserve dedicated, evidence-based investment in their own well-being. ICONIQ Impact welcomes additional philanthropists to join the Co-Lab's founding donors in supporting this work.

Boys and men in the United States are navigating a well-documented set of challenges: troubling suicide rates, rising rates of loneliness and social isolation, a widening gap in educational attainment, and children growing up without a father at home. Men account for nearly 80% of U.S. suicide deaths1 and roughly one in four young men report feeling lonely a lot of the previous day2. Men are 17 percentage points less likely than women to earn a bachelor's degree3. Nearly one in four children in the U.S. — 18.2 million — live without a father figure at home[4].

Such a diverse set of challenges calls for multiyear, evidence-based investment in solutions that already work, along with support for promising new approaches. Despite that need, very little U.S. philanthropic giving is designated specifically for boys and men5.

"Boys and men are struggling — in classrooms, in the labor market, and in their sense of connection to the people around them — and solving that requires philanthropy willing to fund what's working and what's promising for boys and men, without strings attached," said Matti Navellou, head of ICONIQ Impact. "On behalf of ICONIQ Impact, we're grateful to our founding donors for stepping up to make this work possible."

The portfolio spans organizations at different stages of growth, many of which have historically been overlooked and underfunded. Consistent with ICONIQ Impact's trust-based approach to grantmaking, each grantee receives unrestricted, three-year funding, with a particular interest in programs built around person-to-person connection.

"As a mother and a philanthropist, I want to help move the conversation about boys and men from documenting the challenges to investing in solutions. There are bright spots across the country, with organizations helping boys and men build connections, find purpose, and create opportunities for their futures," said Jessica Sieja, founder of Alta Futures. "This Co-Lab gives us a chance to back that work together and help shape a more hopeful narrative."

"Men and boys are increasingly disconnected from family and community, frustrated by school, and anxious about their economic prospects. Such feelings, and the legitimate grievances behind them, lead some to conclude that democracy is failing them," said Ben Chou, Interim Director for Democracy, Rights, and Governance at The David and Lucile Packard Foundation. "That's why we're proud to join the Boys & Men Co-Lab as a founding donor — it reflects the kind of collaborative, evidence-based philanthropy we believe in, and we're glad to stand alongside ICONIQ Impact and our fellow donors in this work."

ICONIQ Impact will lead the Co-Lab's ongoing grantee engagement and impact measurement over its multiyear grant period and is inviting additional philanthropists to join the Co-Lab's founding donors in building out the portfolio.

The Boys & Men Co-Lab is the newest addition to ICONIQ Impact's broader portfolio of Co-Labs, which spans issues from ocean conservation and climate equity to youth mental health and women's health.

"For too long, the challenges facing boys and men have been treated as a footnote in philanthropy instead of a priority," said Richard V. Reeves, author of Of Boys and Men: Why the Modern Male Is Struggling, Why It Matters, and What to Do About It, and a leading expert on the issues facing boys and men in America. "The evidence on what boys and men need — belonging, purpose, engaged fathers, schools that work for them — is not new. What's been missing is philanthropy willing to invest in it. The Boys & Men Co-Lab is that investment."

The Boys & Men Co-Lab's initial portfolio spans the following three pillars:

1. Community

The Co-Lab's community partners are strengthening friendships through shared activities and gathering spaces and creating new opportunities for boys and men to build purpose through civic engagement.

Grantees:

Fishing the Good Fight, National Compadres Network, Young Man with a Plan, Walking Talking Men, Big Brothers Big Sisters of Orange County and the Inland Empire, and Civic Valor (The Brickyard).

Impact:

- In a four-year, randomized controlled trial, youth mentored through Big Brothers Big Sisters were 30% less likely to be involved in the juvenile justice system and 42% less likely to use illicit substances.

- At Young Man with a Plan, a Boston mentoring program led by Executive Director Dr. Jaykyri Simpson, that same sense of belonging takes shape in its 6,720-square-foot afterschool "home" where members share study spaces, fitness area, a kitchen, and a standing community of mentors and peers. Every young man builds an individualized success plan, and seniors consistently graduate from high school at a rate of 100%.

2. Fatherhood

The Co-Lab's fatherhood partners are strengthening fatherhood education and peer support and working to remove structural barriers to engaged fatherhood.

Grantees:

Fathers' UpLift, Dad Guild, Fathers, Families & Healthy Communities, Center for Urban Families, Fathers Incorporated, and National Parents Organization.

Impact:

- Dad Guild, a grassroots father network founded in Vermont, has grown from a single group of new dads into a statewide movement. In its most recent survey, 67% of fathers who attended three or more events said they'd made new friendships through the program, and participants named an average of more than five people they could turn to for support.

- In Chicago, Fathers, Families & Healthy Communities — led by Dr. Clinton Boyd Jr. — is building on more than a decade of trusted work with Black fathers through Fathers United, a 25-session peer cohort. In its first year, the program helped roughly 80 fathers strengthen their relationships with their children.

- Fathers Incorporated is working to remove the legal and administrative barriers that can keep noncustodial fathers from staying involved in their children's lives. That work has helped move legitimation reform for unmarried fathers into active legislative consideration in Georgia.

3. Education and Skills

The Co-Lab's education and skills partners are improving belonging and supportive relationships in schools and making educational environments more responsive to how boys learn and succeed.

Grantees:

100 Black Men of America, Boys to Men Mentoring Network (San Diego and Virginia), Journeymen, Eagle Academy Foundation, Boys Who Write, and Call Me MISTER.

Impact:

- In North Carolina, Journeymen brings boys from different backgrounds together in peer-led mentoring circles and rites-of-passage weekends. In a recent survey, 100% of participants reported feeling more hopeful about the future, and more than 80% said they'd improved their ability to set goals and express their emotions.

- Boys to Men Mentoring Network, which pioneered the mentoring-circle model in San Diego and has since expanded into Virginia, is now building the shared training infrastructure to bring that model to communities nationwide.

About ICONIQ Impact

ICONIQ Impact is ICONIQ Capital's platform for collaborative philanthropy. Guided first and last by the communities it works with, ICONIQ Impact convenes its community to tackle some of the world's most urgent challenges, prioritizing learning, collective action, and equity at every step. Since launching in 2019, ICONIQ Impact's community has directed more than $1 billion toward the world's most pressing challenges through its Co-Labs, Impact Portfolios, Awards, and philanthropic advisory services. ICONIQ Impact serves as a philanthropic advisor to the third-party sponsoring the Boys & Men Co-Lab and receives compensation for its advice.

Media Contact:

For additional comment or impact statistics about any of the grantees above, please contact:

Amy Enright, Newton Street, [email protected]

(AIBM)

(National Fatherhood Initiative, citing U.S. Census Bureau data).

(Candid)

SOURCE ICONIQ Capital

Share this article

HSG Laser Unveils New Flagship Machine at EuroBLECH 2026, Powering Productivity for European Manufacturers

HANNOVER, Germany, Oct. 21, 2026 /PRNewswire/ -- HSG Laser is showcasing its latest laser cutting and intelligent manufacturing solutions at EuroBLECH 2026, held from October 20–23 at the Hannover Exhibition Centre. Under the theme "Powering Productivity with HSG," HSG is presenting its latest innovations at Booth 15-F42, including the European debut of its new flagship GV, alongside the launch of GFA PRO and AI CutPilot, as well as the European debut of its high-speed laser solutions G3015T and R2 PRO.

Expanding High-Performance Laser Solutions

The new GFA PRO is engineered for large-format metal processing, addressing challenges such as large footprints, low speed, unstable thick-plate performance, and high operating costs. Making their European debut, the G3015T and R2 PRO expand HSG's high-speed laser lineup for sheet and tube processing, helping manufacturers improve throughput, flexibility, and production efficiency.

"HSG Laser's European footprint has grown steadily, with more than 2,000 units delivered and a new showroom opening soon this year," said Shawn Wang, Vice President of HSG Laser. "Our latest launches at EuroBLECH mark another step forward, combining high-performance equipment with intelligent technologies and localized support to deliver greater productivity for European customers."

Recognized by MM MaschinenMarkt Germany

Built for the European market, HSG Laser earned the "International Spotlight" award from MM MaschinenMarkt Germany's Chief Editor for its GV and AI CutPilot. The GV combines cutting, beveling, countersinking, and chamfering in one machine to streamline pre-welding workflows and boost efficiency. AI CutPilot is HSG's industry-first, self-developed AI system that turns laser-cutting expertise into a reusable, scalable machine capability, helping reduce trial work and improve first-pass yield. The award further highlights HSG Laser's technological strength and growing presence in the European market.

Strengthening Local Operations in Europe

As part of its continued commitment to supporting manufacturers worldwide, HSG Laser is further strengthening its localized operations in Europe. On 10th November, HSG will open its new showroom in Düsseldorf, Germany under the theme "Go Global, Link Local." The new showroom will bring HSG's latest machines, technologies, and expertise closer to European customers, creating more opportunities for direct engagement and local support. This expansion further strengthens HSG's presence in Europe and its ability to provide responsive, customer-focused solutions tailored to local manufacturing needs.

About HSG Laser

Founded in 2006, HSG Laser is a leading global manufacturer of intelligent metal processing equipment, specializing in laser cutting, tube processing, bending, and welding automation systems. With a presence in over 100 countries and regional centers across Europe, North America, Japan, India, and Asia-Pacific, HSG Laser is committed to driving the transformation of manufacturing through innovation, reliability, and artificial intelligence.

Share this article

More Than 1 in 3 Americans Have a Tool or Appliance Upgrade on Hold, VEVOR Home Improvement Report Finds

Kitchen gear tops the backlog and price is the No. 1 reason for waiting. Only 1 in 10 strongly agree pro-level results require the most expensive tools.

HOUSTON, Oct. 21, 2026 /PRNewswire/ -- More than a third of Americans (35%) have a tool or appliance at home they've been meaning to upgrade but haven't, and two-thirds of them have been putting it off for six months or longer, according to The VEVOR Home Improvement Report: Black Friday Edition, a new survey from home improvement brand VEVOR.

Key Findings

- 35% of Americans have a tool or appliance upgrade on hold; 66% of them have waited six months or more

- Kitchen equipment (25%), power tools (20%) and lawn and yard equipment (15%) top the backlog

- Price is the top reason for waiting (44%); another 17% are holding out for a sale

- 1 in 5 Americans (21%) plan to buy home improvement tools or equipment this Black Friday–Cyber Monday

- Only 9% strongly agree that pro-level results require the most expensive tools; 66% lean the other way

- Among home improvement shoppers, the backyard and garden (41%), kitchen (34%) and garage or workshop (31%) top next year's upgrade plans

The Upgrade Backlog

Among Americans with a pending upgrade, the items waiting to be replaced span the categories most households manage:

- Kitchen equipment and appliances: 25%

- Power tools: 20%

- Lawn and yard equipment: 15%

- Outdoor and patio equipment: 10%

- Vehicle maintenance tools: 9%

- Hand tools: 7%

- Garage storage: 6%

For two-thirds of them (66%), the wait has lasted six months or longer. Among Americans with an upgrade on hold, 31% have been waiting less than six months, another 35% for six months to a year, 22% for one to two years and 9% for more than two years.

Why It's on Hold

Price tops the list. Among Americans with an upgrade on hold, 44% said the price is more than they want to spend — more than seven times the 6% who cited concerns about the quality of unfamiliar brands. Another 17% said they are holding out for a sale, 15% said the item still works, 9% were unsure which product to buy and 7% said they had not had time to research.

Black Friday Plans

Roughly 1 in 5 Americans (21%) have already decided, or are very likely, to buy a home improvement tool or piece of equipment during this year's Black Friday and Cyber Monday period. Add the 30% who say they might, and the share rises to 51%.

Among those planning to buy, price sensitivity is clear. The $100–$249 range is the most common target, picked by 39% of intending buyers, and 77% plan to spend less than $500.

Pro-Level ≠ Most Expensive

When Americans were asked to rate their agreement with the statement "To get professional-level results on a home improvement project, you have to buy the most expensive tools," on a scale of 1 (disagree) to 10 (agree), only 9% gave the statement an 8–10 rating. Roughly two-thirds (66%) rated the statement between 1 and 5.

Where Shoppers Plan to Upgrade Next

Among U.S. adults identified through YouGov profile data as having an interest in home improvement and DIY, the spaces they expect to tackle over the next year cluster around the home's everyday working areas. Respondents could choose more than one:

- Backyard and garden: 41%

- Kitchen: 34%

- Garage or workshop: 31%

- Patio: 29%

- Exterior: 25%

- Storage: 24%

Figures for backyard and garden through storage are based on the home improvement sample and are not nationally representative.

DIY Culture

Americans remain hands-on. Among U.S. adults surveyed, 59% reported personally completing hands-on work on at least one home, yard, garage or vehicle project in the past 12 months — 32% did most of the work themselves and another 27% worked on it with family or friends. Just 8% handed projects off entirely to professionals.

3 Tips Before You Upgrade This Black Friday

- Start with the space you use most. For many shoppers, that's the backyard or the kitchen.

- Read user reviews, not just specs. Look for verified reviews from people who used the product on a similar project.

- Match the tool to the job, not the brand name. With only 9% of Americans strongly agreeing that pro-level results require the most expensive tools, fit and features matter more than a familiar label.

"Most people have one thing at home they've been meaning to upgrade — the mower that barely starts, the drill with a battery that won't hold a charge," said Gavin Wu, Brand Director at VEVOR. "Price is what keeps it on the list. And very few shoppers believe you need the most expensive tool to get a professional result."

Full results, charts and methodology are available at The VEVOR Home Improvement Report. Journalists can request breakdowns by age and income, or an interview with Gavin Wu.

About the Survey

The VEVOR Home Improvement Report: Black Friday Edition is based on two online surveys conducted by VEVOR using YouGov Surveys: Self-serve between September 24 and October 2, 2026.

The national sample comprises 804 U.S. adults aged 18 and over, weighted by age, gender and region. The home improvement sample comprises 1,002 U.S. adults identified through YouGov profile data as interested in home improvement and DIY and having completed a major home improvement project in the past 12 months. Figures describing Americans are based on the national sample. Figures describing home improvement shoppers are based on the home improvement sample and are not nationally representative.

About VEVOR

VEVOR is a leading global home improvement brand built on a simple promise: Pro-Level Performance Without the Pro-Level Price. From tools, garden and outdoor to kitchen, storage and automotive, VEVOR helps Home Creators upgrade their spaces with confidence. Today, VEVOR has supported over 30 million Home Creators worldwide.

Media Contact

VEVOR Communications Team

[email protected]

SOURCE VEVOR

Share this article

Purchase of 130,000 SF facility to expand capacity for space-based hardware and sensor system production

BROOMFIELD, Colo., Oct. 21, 2026 /PRNewswire/ -- BAE Systems (LON: BA) announced today that it has closed on the purchase of a 130,000 square-foot production facility in Weld County, Colorado. The building, located on approximately 13 acres, will enhance the company's manufacturing capabilities to meet customer demand and business growth related to space-based hardware and sensor systems.

"We look forward to expanding our production capabilities in Colorado with our first facility in Weld County," said Alexis Wang, vice president of operations for BAE Systems. "The support we received from the Weld County Commissioners and the State of Colorado played a key role in our ability to locate this essential production work for the company in Colorado, extending our manufacturing presence in the state."

BAE Systems expects to hire more than 200 new employees to support production at the new Weld County facility over the next 12 to 24 months. At full capacity, the company estimates that the new facility could feature approximately 600 employees.

"Weld County is excited to welcome and partner with BAE Systems as they establish a new production facility in Northern Colorado," said Scott James, Chair of the Weld County Board of Commissioners. "Projects of this scale are transformational, not only because of the capital investment and high-quality employment they bring, but because they strengthen the entire industry ecosystem and create new opportunities for businesses, workers, and families across the region. This industry provides skilled high-paying jobs for both factory workers and engineers, and this represents a strong opportunity for economic growth and diversification."

BAE Systems plans to begin the retrofit process of the facility and procuring equipment throughout the rest of the year and anticipates opening the facility for production in early 2028.

"Colorado continues to lead the nation in aerospace and advanced manufacturing, and we are thrilled to welcome BAE Systems' expansion in Weld County," said Colorado Gov. Jared Polis. "This investment will bring hundreds of good-paying jobs to Weld County and further solidify our state as a hub for cutting-edge technology and innovation."

The addition of the Weld County facility expands BAE Systems' presence in Colorado, joining nearby production facilities in Boulder, Broomfield and Westminster.

For more information, please contact:

Brian Rantala, BAE Systems

Mobile: 720-995-8253

[email protected] 

www.baesystems.com/US

@BAESystemsInc 

SOURCE BAE Systems, Inc.

Share this article

RISION Launches Torix, a Standalone Handheld Thermal Camera Bringing Professional Inspection Detail

A ready-to-use thermal camera with 320×240 clarity and a 10-hour battery—works straight out of the pocket for professionals and homeowners.

HONG KONG, Oct. 21, 2026 /PRNewswire/ -- RISION, a global technology brand specializing in thermal imaging and intelligent sensing, today announced the launch of RISION Torix, its standalone handheld thermal camera.

The RISION Torix is a fully self-contained thermal camera built for professionals who inspect often and work with both hands, from HVAC technicians and building inspectors to auto specialists and serious DIYers. It delivers professional-grade detail and durability at an approachable price, making it the go-to tool for those who need performance they can rely on, without the premium markup.

"Torix is the thermal camera we wanted to put in every toolbox," said York Guo, founder and CEO of RISION. "With the RISION Magic series selling hot, Torix completes our lineup. It's built more rugged for users who need to work without worry in tougher environments. We know how much time and money a single undetected fault can cost, whether it's an overheating panel or a hidden leak. Torix puts that visibility in your hands".

More Detail at the Same Distance

The RISION Torix is built around a native 160 × 120 infrared sensor, a higher native resolution than directly competing thermal cameras in its tier. It's enhanced to 320 × 240 by RISION's QuadIR™ super resolution. Thermal sensitivity of ≤40 mK reveals subtle temperature differences and a 25 Hz frame rate keeps scanning smooth. A 2.6 mm fixed-focus lens delivers higher optical magnification than comparable thermal cameras, so small components can be examined close up and distant targets remain distinguishable without stepping closer to overheating equipment. It is a genuinely one-instrument tool, with measurements spanning -4 °F to 1,022 °F (-20 °C to 550 °C) at ±2 °C or ±2 % accuracy. That range is enough for underfloor heating checks, electrical panels, and high-temperature processes alike.

Rugged, Reliable, And Always Ready

The RISION Torix starts instantly and displays the image on a built-in 2.8-inch screen with six color palettes. Its 2,750 mAh battery delivers ten hours or more of continuous use — a full day of inspections, and recharges in 60 minutes. The device also holds its charge during long-term storage, so it's ready when you need it. IP54 protection against dust and splashes and 2-metre drop resistance mean it can be treated like any other tool in the bag.

From Alert to Report in One Workflow

RISION Torix supports custom high and low temperature limits, triggering a visual red alert and automatically capturing a full-radiometric image when either threshold is crossed. Interval capture down to 10 seconds ensures that intermittent faults are fully documented without the need for continuous screen monitoring. JPEG images and MP4 video are saved to a replaceable SD card and transfer over USB-C or by removing the card, with no software required. For deeper work, the free RISION Smart software for Windows adds point, line and area measurement, editing and professional report generation.

Pricing and Availability

The RISION Torix is now available for pre-order in both the US and the UK via the company's official website. The device is priced at $219 in the US and £229 in the UK, with RISION offering early-bird discounts of $50 and £80 respectively, bringing the early-bird price to $169 and £149. US open sales begin November 16 on RISION's official website and Amazon, with the UK to follow in late November.

For more information, please visit RISION's official website.

About RISION

RISION is a global technology brand specializing in thermal imaging and intelligent sensing. Its team brings more than 20 years of experience across optical engineering, artificial intelligence, sensor technology and precision manufacturing. The company reports a portfolio of more than 100 granted and pending patents.

Learn more at www.rision.com.

Share this article